These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 33022650)
1. Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All? Garcia-Horton A; Lipton JH J Natl Compr Canc Netw; 2020 Oct; 18(10):1421-1428. PubMed ID: 33022650 [TBL] [Abstract][Full Text] [Related]
2. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237 [TBL] [Abstract][Full Text] [Related]
3. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758 [TBL] [Abstract][Full Text] [Related]
4. Treatment-Free Remission: the New Goal in CML Therapy. Atallah E; Sweet K Curr Hematol Malig Rep; 2021 Oct; 16(5):433-439. PubMed ID: 34618317 [TBL] [Abstract][Full Text] [Related]
5. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Shanmuganathan N; Pagani IS; Ross DM; Park S; Yong ASM; Braley JA; Altamura HK; Hiwase DK; Yeung DT; Kim DW; Branford S; Hughes TP Blood; 2021 Mar; 137(9):1196-1207. PubMed ID: 32871588 [TBL] [Abstract][Full Text] [Related]
8. Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective. Saglio G; Sharf G; Almeida A; Bogdanovic A; Bombaci F; Čugurović J; Deekes N; Garcia-Gutiérrez V; de Jong J; Narbutas Š; Westerweel P; Zackova D Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):375-379. PubMed ID: 29753691 [TBL] [Abstract][Full Text] [Related]
9. Deep molecular responses for treatment-free remission in chronic myeloid leukemia. Dulucq S; Mahon FX Cancer Med; 2016 Sep; 5(9):2398-411. PubMed ID: 27367039 [TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice. Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694 [No Abstract] [Full Text] [Related]
11. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data. Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205 [TBL] [Abstract][Full Text] [Related]
12. SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML). Mikhaeel S; Atallah E Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):333-339. PubMed ID: 36934065 [TBL] [Abstract][Full Text] [Related]
13. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Mahon FX; Etienne G Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905 [TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukaemia: Biology and therapy. Wang Y; Liang ZJ; Gale RP; Liao HZ; Ma J; Gong TJ; Shao YQ; Liang Y Blood Rev; 2024 May; 65():101196. PubMed ID: 38604819 [TBL] [Abstract][Full Text] [Related]
16. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia. Caldemeyer L; Akard LP Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641 [TBL] [Abstract][Full Text] [Related]
17. Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia. Elsayed AG; Srivastava R; Jamil MO Curr Oncol Rep; 2017 Oct; 19(12):77. PubMed ID: 28988389 [TBL] [Abstract][Full Text] [Related]
18. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. Ercaliskan A; Eskazan AE Cancer; 2018 Oct; 124(19):3806-3818. PubMed ID: 29694669 [TBL] [Abstract][Full Text] [Related]
19. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy. Ali MA Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498 [TBL] [Abstract][Full Text] [Related]